Results 41 to 50 of about 10,093 (182)

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Omalizumab: Clinical Use for the Management of Asthma

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2012
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β 2 agonist
Neil C. Thomson, Rekha Chaudhuri
doaj   +1 more source

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA, 2020
Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients
Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi   +8 more
doaj   +1 more source

Optimising the Diagnosis of Sesame Seed Allergy With the Basophil Activation Test

Allergy, EarlyView.
The basophil activation test (using the activation marker CD203c) was the only test able to both exclude and confirm sesame seed allergy with precision. A negative skin prick test to sesame extract or tahini and undetectable IgE to Ses i 1 could not rule out sesame seed allergy.
Ru‐Xin Foong, Irene Bartha, Holly Boyd, Andreina Marques‐Mejias, Suzana Radulovic, Marta Krawiec, Faye Harrison, Malak Eghleilib, Grammatiki Antoneria, Zainab Jama, Matthew Kwok, Vasco Claro, Cristian Ricci, Tom Marrs, Gideon Lack, George Du Toit, Alexandra F. Santos   +16 more
wiley   +1 more source

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Journal of Immunology Research, 2016
IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies ...
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina, Margarita Martín   +3 more
doaj   +1 more source

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

Indian Dermatology Online Journal, 2016
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines.
Kiran Godse, Murlidhar Rajagopalan, Mukesh Girdhar, Sanjiv Kandhari, Bela Shah, Prashant N Chhajed, Sushil Tahiliani, D S Krupa Shankar, Vijay Somani, Vijay Zawar   +9 more
doaj   +1 more source

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge

Allergy, EarlyView.
High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion, S. Villazala‐Merino, C. Morgenstern, L. Nemec, V. Stanek, A. Tu, M. Zghaebi, J. Toth, R. Fröschl, T. Perkmann, M. Bastl, K. Gangl, S. Schneider, H. Breiteneder, R. Ristl, M. Focke‐Tejkl, R. Valenta, V. Niederberger‐Leppin, J. Eckl‐Dorna   +18 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab can provide clinical benefits to a fraction of moderate-to-severe asthma patients. However, the mechanisms of action of omalizumab have not been fully understood.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Mark Millard, MD, Matthew Wiest, PhD, Chao Gu, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source